Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement, named ‘STarT Pancreas’, to identify and validate new therapeutic targets in Pancreatic Ductal Adenocarcinoma.
The three-year agreement between Oncodesign Precision Medicine (OPM) and Servier includes two steps: Co-construction of an AI analytical platform based on data generated in the OncoSNIPE clinical trial® and identification of targets with this platform; then experimental validation of the pre-selected targets.
“We are delighted to initiate this collaboration with OPM, and to contribute to the development of an AI-based data analysis solution that could enable us to identify new therapeutic targets in pancreatic ductal adenocarcinoma, a dreaded cancer increasing in industrialized countries. This partnership is in line with the Group’s strategy of making the fight against cancer one of its strategic priorities, targeting hard-to-treat cancers for which treatment options are limited.”
Dr. Walid S. Kamoun, Servier’s Director of R&D Oncology
Pancreatic cancer is considered as one of the most difficult cancers to treat, due to its insidious symptoms and high degree of malignancy leading to a high mortality rate.
Learn more about pancreatic cancer
Servier and Oncodesign are also engaged in a research collaboration in Parkinson’s disease since 2019.
Read more.